Clinical investigation of an aluminumtriformate mouthrinse; a double blind trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00007672

Enrollment

Registered

2015-01-21

Start date

2013-08-13

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

K05.1

Interventions

Group 1: Aluminumtriformate mouthrinse (Cional ®, 3x daily, 30 seconds each over a seven days period. Group 2: Placebo mouthrinse, 3x daily 30 seconds each over a seven days period

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: History of chronic periodontitis, having had active periodontal treatment including non-surgical and surgical therapies and bein in maintenance for = 1 year; = 18 years old; willing to participate and willing to sign the informed consent; Having a modified sulcus bleeding index (MSBI) of = 40 %; No pocket depths = 6 mm; at least 20 teeth (at least 5 teeth in each quadrant); systemically healthy

Exclusion criteria

Exclusion criteria: Known hypersensitivity to ATF; known hypersensitivity to other ingredients of Cional® (Cremophor RH40, peppermint oil, mint oil, propylene glycol, glycerol); any antibiotic therapy < 3 months before treatment; smoker; pregnancy or wish for pregnancy; participation in another clinical study; lack of ability to participate in the screening appointments.

Design outcomes

Primary

Measure	Time frame
The reduction of gingival bleeding is determined at baseline and after seven days using MSBI score.	—

Secondary

Measure	Time frame
Theinfluence on plaque formation is determined at baseline and after seven days using API score.	—

Countries

Germany

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Mar 13, 2026